AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUL 306 min read$CERS

Cerus Corporation Announces Second Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Second Quarter 2026 Financial Results Second Quarter 2026 Total Revenue of $63.3 million; Second Quarter 2026 Product Revenue of $57.4 million, +10% Y/Y Raising Lower End of 2026 Product Revenue Guidance: Range now $229 to $231 million; Ra

Original reporting
SEC EDGAR 8-K
Published Jul 30, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CERS
Bullish
medium confidence
Mentioned
$CERS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CERSBullishMed
01

Why it matters

Traders can update expectations for 2026 revenue growth and IFC contribution based on the raised guidance range, while monitoring gross margin pressure and cash usage tied to inventory build.

02

Market read

The most tradable elements are the raised 2026 product revenue and IFC guidance, plus the disclosed regulatory timeline and debt refinancing details.

03

What to watch

The filing notes a regulatory decision for the INT200 platelet system is not expected until early 2027, so near-term upside may rely more on IFC volumes and working-capital/inventory dynamics than on the next-generation device.

Relevance 7/10Novelty 7/10Timing: after-hours guidance and results released; conference call at 4:30 P.M. ET today

Background

Cerus reported Q2 2026 results and provided an update on its INTERCEPT franchise, including regulatory progress for the INT200 illuminator and BARDA collaboration expansion.

Company-level read

Ticker impact

$CERSBullishMedium confidence
Context

Cerus raised 2026 product revenue guidance to $229 to $231 million and increased IFC outlook to $23 to $25 million.

Expected impact

Likely upward bias for the stock into/after the earnings call, with follow-through dependent on gross margin trajectory and cash burn.

Evidence & confidence

The filing discloses multiple decision-relevant datapoints: raised revenue and IFC guidance, PMA submission for INT200 with FDA decision expected early 2027, and completed debt refinancing. Offsetting factors include product gross margin down to 51.4% from 55.2% and cash declining to $56.3 million from $82.9 million at year-end.

Market effects

Sector

Reinforces demand momentum for pathogen-reduced blood components and the growth narrative around Cerus’ INTERCEPT franchise.

Regional

Limited, primarily affects US-listed biotech sentiment and investor positioning in medical technology/blood safety names.

Global

IFC demand is described as increasing globally, but the disclosed financial impact is most specific to US sales and guidance.

Counterpoint

What could challenge this read

Margin compression and declining cash could cap upside despite guidance raises, especially if inflation and FX headwinds persist.

Key entities

  • issuer
    Cerus Corporation

    Nasdaq-listed blood products company reporting Q2 2026 results and raising 2026 product revenue and IFC guidance.

  • product_franchise
    INTERCEPT Fibrinogen Complex (IFC)

    Pathogen-reduced fibrinogen product line with disclosed volume growth and raised 2026 revenue outlook.

  • regulatory_event
    FDA PMA for INTERCEPT Blood System for Platelets with INT200 Illuminator

    Next-generation LED-based illumination device; PMA submitted with decision anticipated in early 2027.

  • government_contract
    BARDA contract (INTERCEPT Red Blood Cell system)

    Collaboration expanded, increasing total potential value of the 2024 contract by $21.9 million to $270.5 million.

Read at source← All news

Related articles

NOV 3
$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

finance.yahoo.com2 min
NOV 2
$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

finance.yahoo.com1 min
NOV 2
$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

finance.yahoo.com4 min
NOV 2
$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

SEC EDGAR 8-K2 min
NOV 2
MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.

stocktitan.net2 min